Bayer and Recursion focus research collaboration on oncology
- Details
- Category: Bayer
Bayer and US-based Recursion Pharmaceuticals, Inc., a clinical stage TechBio company decoding biology to industrialize drug discovery, announced that they have updated the focus of their research collaboration to precision oncology.
The oncology-focused collaboration will leverage Bayer's small molecule compound library and expertise in biology and medicinal chemistry as well as Recursion’s purpose-built artificial intelligence-guided drug discovery platform.
Bayer expands global life science incubator network
- Details
- Category: Bayer
Bayer AG today announced the global expansion of its life science incubator network, Bayer Co.Lab, to Shanghai, China, and Kobe, Japan.
This move establishes new sites for the Bayer Co.Lab program at the hotspots of innovation in China as well as in Japan.
Bayer and Broad Institute of MIT and Harvard extend research collaboration to develop new cancer therapies
- Details
- Category: Bayer
Bayer and the Broad Institute of MIT and Harvard today announced that they have extended their research collaboration of 10 years by an additional five years, to develop and advance innovative cancer treatments. The expanded agreement will focus on joint cancer target identification and discovery of new therapeutic approaches in oncology.
AstraZeneca announces collaboration and investment agreement with Cellectis to accelerate cell therapy and genomic medicine ambitions
- Details
- Category: AstraZeneca
AstraZeneca today announced a collaboration and investment agreement with Cellectis, a clinical-stage biotechnology company, to accelerate the development of next generation therapeutics in areas of high unmet need, including oncology, immunology and rare diseases.
Pfizer and BioNTech announce positive topline data for mRNA-based combination vaccine program against influenza and COVID-19
- Details
- Category: Pfizer
Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced positive topline results from a Phase 1/2 study (NCT05596734) evaluating the safety, tolerability and immunogenicity of mRNA-based combination vaccine candidates for influenza and COVID-19 among healthy adults 18 to 64 years of age.
Roche enters into a definitive agreement to acquire Telavant including rights to novel TL1A directed antibody (RVT-3101) for the treatment of inflammatory bowel disease from Roivant
- Details
- Category: Roche
Roche (SIX: RO, ROG; OTCQX: RHHBY) announced the entry into a definitive agreement to acquire Telavant Holdings, Inc. (Telavant), a Roivant company, owned by Roivant Sciences Ltd. and Pfizer Inc.. The agreement includes the development, manufacturing and commercialisation rights in the US and Japan for Telavant's RVT-3101, a novel TL1A directed antibody.
AskBio contribution to advancing gene therapy highlighted at ESGCT 30th Congress
- Details
- Category: Bayer
Asklepios BioPharmaceutical, Inc. (AskBio), a wholly owned and independently operated subsidiary of Bayer AG, announced that 20 company abstracts will be presented at the European Society for Gene and Cell Therapy (ESGCT) 30th Congress, which is being held in Brussels, Belgium, from October 24 to 27, 2023.
More Pharma News ...
- FDA approves PENBRAYA™, the first and only vaccine for the prevention of the five most common serogroups causing meningococcal disease in adolescents
- CPHI Annual Survey: global pharma resilient with India the chief beneficiary of macro changes
- U.S. FDA approves Pfizer's BRAFTOVI® + MEKTOVI® for BRAF V600E-mutant metastatic non-small cell lung cancer
- Bayer invests 250 million USD in new cell therapy manufacturing facility in the U.S.
- Pfizer presents new data at IDWeek 2023 highlighting advances in prevention and treatment of certain respiratory illnesses and other infectious diseases
- Bayer to partner with Twist Bioscience to accelerate drug discovery
- Novartis shareholders approve the proposed 100% Spin-off of Sandoz